8-K: Vycor Medical Reports Strong Q2 Revenue & Profit Growth

Vycor Medical announced significant revenue and operating profit increases for Q2 2025, driven by international expansion of its neurosurgery division.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 22% to $496,353 compared to $406,278 in the same period of 2024.
• Total revenue for the six months ended June 30, 2025, increased by 25% to $932,731 compared to $743,246 in the same period of 2024.
• The Vycor Medical division (VBAS) saw revenue growth of 24% for Q2 2025 and 28% for H1 2025, primarily from international markets.
• GAAP operating profit for Q2 2025 was $51,146, a substantial increase from $16,178 in Q2 2024.
• Non-GAAP operating profit for Q2 2025 was $84,481, up from $31,859 in Q2 2024.
• The company reported GAAP net income of $23,887 for Q2 2025, a significant improvement from a net loss of $(10,038) in Q2 2024.
• New distribution agreements were established for France and Spain, targeting international expansion.
• Two new clinical papers on the ViewSite Brain Access System (VBAS) were published in Q2 2025, bringing the total to 48 peer-reviewed studies.
• A new clinical study validated NovaVision's NeuroEyeCoach for both home-based and clinic-based use, showing meaningful improvements with no significant differences in activities of daily living improvements.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong revenue growth in the core medical device segment, significant improvements in GAAP and non-GAAP operating profits, and a shift to net income in the quarter. Strategic international expansion and positive clinical study results for both divisions further bolster the positive outlook, despite a slight revenue decline in the developing NovaVision segment and a dip in gross margin.

Positives

• Overall revenue increased by 22% for the three months and 25% for the six months ended June 30, 2025.
• Vycor Medical division revenue grew by 24% in Q2 and 28% in H1, largely due to international market expansion.
• GAAP operating profit significantly increased to $51,146 in Q2 2025 from $16,178 in Q2 2024, and to $38,340 in H1 2025 from $6,646 in H1 2024.
• Non-GAAP operating profit showed substantial increases, reaching $84,481 in Q2 2025 and $106,944 in H1 2025.
• The company achieved GAAP net income of $23,887 in Q2 2025, reversing a net loss of $(10,038) in Q2 2024.
• New distribution agreements in France and Spain indicate successful international market penetration.
• Continued clinical validation of VBAS with two new peer-reviewed papers, highlighting its clinical advantages.
• NovaVision's NeuroEyeCoach program was validated by a new clinical study, confirming its effectiveness for both home and clinic use, which is crucial for digital health adoption.

Negatives

• Gross profit margin decreased to 83% in Q2 2025 from 91% in Q2 2024, attributed to validation and shipping costs of new production and geographical sales mix.
• NovaVision division revenue decreased by 23.5% for Q2 2025 to $14,565 and by 13.3% for H1 2025 to $32,423, as it remains in development.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which could cause actual results, performance, or achievements to differ.
• Risks, uncertainties, and other factors are more fully discussed in Vycor Medical's other filings with the U.S. Securities and Exchange Commission; this filing does not detail specific risks.

Future Outlook

The company continues to focus on international expansion for its Vycor Medical division and further development of its NovaVision therapies, which still require significant development to address their market potential. The validation of home-based digital technologies like NeuroEyeCoach is seen as important given the global drive in healthcare systems.

Management Comments

• Management believes that non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of ongoing operating results and trends, compared with historical results.
• Management uses non-GAAP measures to measure the performance of ongoing operating results against prior periods and against internally developed targets.

Industry Context

The report highlights a growing trend in minimally invasive neurosurgery with the success of VBAS, which aligns with broader healthcare shifts towards less invasive procedures and improved patient outcomes. The validation of NovaVision's NeuroEyeCoach for home-based use is particularly relevant given the global push for digital health technologies and remote patient care, especially for chronic conditions or post-injury rehabilitation.

Comparison to Industry Standards

• The ViewSite Brain Access System (VBAS) is approved and used in over 300 hospitals in the US and numerous countries internationally, indicating significant market penetration for a specialized neurosurgical device.
• NovaVision's Visual Restoration Therapy (VRT) is noted as the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, positioning it uniquely in the market.
• The NeuroEyeCoach program is supported by a 296-patient study, described as the largest to date in the neuro visual space, providing strong clinical backing for its efficacy.

Related Party Transactions

• Interest expense related to a related party was $(12,572) for the three months ended June 30, 2025, and $(25,142) for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders are positively impacted by strong revenue growth, improved profitability, and the company's strategic expansion and clinical validation efforts.
• Patients benefit from the continued availability and clinical validation of minimally invasive neurosurgical solutions (VBAS) and vision rehabilitation therapies (NovaVision), including validated home-based options.
• Healthcare systems may see increased adoption of digital health technologies due to the validation of remote therapy programs like NeuroEyeCoach.

Next Steps

• Continue international expansion efforts for the Vycor Medical division.
• Further develop NovaVision therapies to address their full market potential.

Key Dates

Recommendation

The company demonstrates robust financial performance with significant revenue growth in its core Vycor Medical division, driven by successful international expansion. The substantial increase in both GAAP and non-GAAP operating profits, coupled with a return to net income for the quarter, indicates improving operational efficiency and financial health. The continued clinical validation of both VBAS and NovaVision, particularly the home-based efficacy of NeuroEyeCoach, positions the company well within growing markets for minimally invasive procedures and digital health solutions. While NovaVision is still developing and gross margins saw a slight dip, the overall trajectory and strategic initiatives suggest strong future potential, making it an attractive investment.

Keywords

Vycor Medical, VBAS, ViewSite Brain Access System, NovaVision, NeuroEyeCoach, Neurosurgery, Vision Rehabilitation, Medical Devices, Digital Health, SEC Filing, Financial Results, Q2 2025, OTCQB: VYCO